-The Times of India NEW DELHI: The health ministry was actively mulling compulsory licensing, apart from price capping, of “orphan drugs” (for rare diseases), when the department of pharmaceuticals abruptly issued an order exempting such medicines from price control, derailing plans to make these drugs affordable. The health ministry discussed price capping and invoking compulsory licence for these “exorbitantly” priced “orphan drugs” at a meeting on January 3, the day when DoP...

-The Times of India NEW DELHI: Healthcare emerged as the buzzword of the 2018-19 Budget, mainly due to the announcement of the Rs 5-lakh healthcare insurance each for 10 crore families, but the sector didn't get mega allocations. For one, the total budget of the health ministry stands at Rs 56,226 crore — an increase of 12% over the previous year. The National Health Policy 2017 indicated that health expenditure would increase...

-Frontline.in The Assembly elections have put under intense scrutiny Narendra Modi’s Gujarat model of development which is touted as worthy of replication throughout the country. Audit reports of the CAG provide ample evidence of it being inefficient, corrupt and not beneficial to the common people. THE standard indicators of development, as is understood in theory and practice, comprise a range of indices, and not necessarily the level of private investment in...

-Livemint.com Govt plans to?help firms revamp manufacturing units,?refurbish machinery,?ensure subsidized power in bid to produce drugs such as penicillin at competitive rates New Delhi: The Department of Pharmaceuticals (DoP), during a meeting on Wednesday, urged pharma companies to strive for self-sufficiency in critical drugs like penicillin, rifampicin and insulin, in a sign of government concern over India’s dependence on Chinese imports. A large number of so-called active pharmaceutical ingredients (APIs), or bulk drugs,...

-The Times of India In a first for a medical device, the public interest provision in the Drug Price Control Order (DPCO) 2013 was used by the National Pharmaceutical Pricing Authority to cap the price of knee implants. The NPPA cited "exorbitant prices being charged from patients in a non-regulated market" and "a failed market system where asymmetry of information between patient and the doctor has resulted into unethical practices and...